Physician profile
Mark A Cline
NPI 1477563898
$9,900.43
in general payments reported to CMS, 2019-2025
48 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,896 · 2020: $1,197 · 2021: $1,747 · 2022: $1,028 · 2023: $1,142 · 2024: $1,128 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.39 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,860.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,614.23 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $883.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $606.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $589.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $553.65 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Lilly USA, LLC | $356.41 | 2020-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $349.13 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.78 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $230.62 | 2019-2025 | Veozah |
| Dexcom, INC. | $216.86 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $180.73 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $163.61 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.40 | 2022-2025 | |
| Axsome Therapeutics, INC. | $135.62 | 2023-2025 | Sunosi, Symbravo, Auvelity |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.